Business
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass., May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 15 at 9:30 a.m. ET.\n\n \n \n \n \n \n \n\n \nA live webcast of the fireside chat can be accessed under \"Events & Presentations\" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.\nAbout Karyopharm Therapeutics\nKaryopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.\nXPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2024-rbc-capital-markets-global-healthcare-conference-302138529.html\nSOURCE Karyopharm Therapeutics Inc.","length":4157,"tagName":"div"}]